Trial Profile

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemsidomide (Primary) ; Dexamethasone (Primary) ; Elranatamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors C4 Therapeutics

25 Mar 2026 According to C4 Therapeutics media release, first patient has been dosed with cemsidomide in this study. Data from all cohorts (75, 50 and 100 µg doses) evaluating cemsidomide in combination with elranatamab is anticipated in mid-2027.
23 Feb 2026 According to C4 Therapeutics media release, further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is expected in mid-2026.
23 Feb 2026 According to C4 Therapeutics media release, Phase 1b trial of cemsidomide in combination with elranatamab is on track to initiate in Q2 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com